They observed that high expression of miR-181a correlated with N-terminal mutations in CEBPA. These mutations account for approximately 90% of CEBPA mutations in AML and enable translation of a truncated CEBPA-p30 isoform. The gene discussed is CEBPA; the disease is acute myeloid leukemia.